Centre de Recherche Clinique, HUG, Rue Gabrielle Perret-Gentil 4
Geneva, 1211, Switzerland
NCT Number: NCT02391688
Phenotyping is an approach largely used for the evaluation of the activity of cytochromes and transporters in vivo. It consists of the administration of probe substances metabolised by a specific cytochrome or transported by P-glycoprotein (P-gp) for example, followed by the determination of a metabolic ratio or the evaluation of the plasmatic or urinary concentrations of the probe substances. The administration of a cocktail containing several probe substances allows the simultaneous evaluation of the activity of several cytochromes and P-gp in a single test.
When a cocktail approach is used it is important to make sure that no drug-drug interactions occur between the probes within the cocktail. The validation of the lack of interactions, which is the aim of the study, consists of demonstrating that there is no difference in the pharmacokinetic parameters and/or metabolic ratios when a probe is administered alone or as part of the cocktail. The Geneva cocktail consists of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam and fexofenadine for the simultaneous phenotyping of CYP1A2, CYP2B6, CYP2C9, CAP2C19, CYP2D6, CYP3A4 and P-gp, respectively.
Probe and metabolite concentrations will be measured in capillary blood using a dried blood spot (DBS) analysis. To further facilitate sampling, a new simple device will be used to ensure the precision of capillary blood collection.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 1
Geneva, 1211, Switzerland
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D
Comparison of caffeine AUC when treatment A or D is administered
Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D
Comparison of dextromethorphan AUC when treatment A or D is administered
Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D
Comparison of flurbiprofen AUC when treatment A or D is administered
Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D
Comparison of midazolam AUC when treatment A or D is administered
Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D
Comparison of omeprazole AUC when treatment A or D is administered
Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8 hours post treatment B or D
Comparison of fexofenadine AUC when treatment B or D is administered
Time frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post treatment C or D
Comparison of bupropion AUC when treatment C or D is administered
Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D
Comparison of paraxanthine/caffeine MRs between treatment A and D
Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D
Comparison of dextrorphan/dextromethorphan MRs between treatment A and D
Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D
Comparison of 4-hydroxyflurbiprofen/flurbiprofen MRs between treatment A and D
Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D
Comparison of 1-hydroxymidazolam/midazolam MRs between treatment A and D
Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A or D
Comparison of 5-hydroxyomeprazole/omeprazole MRs between treatment A and D
Time frame: 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post treatment C or D
Comparison of 4-hydroxybupropion/bupropion MRs between treatment C and D
Time frame: at each drug administration day
Time frame: 0.5, 1, 2, 3, 4, 6, 8 hours post treatment A, B, C and D
Jules Desmeules
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06566794
Drug Interaction
Helsinki, Finland
View Trial DetailsNCT07308041
Deglutition Disorders, Digestive System Diseases
Uppsala, Sweden
View Trial DetailsNCT06930872
Drug Interaction
Adelaide, South Australia, Australia
View Trial DetailsNCT04463576
Drug Interaction
Bordeaux, France
View Trial Details